Journal
MOLECULAR PSYCHIATRY
Volume 15, Issue 6, Pages 629-636Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2009.121
Keywords
H-1-MRS; schizophrenia; NAA; glutamate; glutamine; antipsychotic drug
Funding
- Mental Illness and Neuroscience Discovery Institute [DE-FG03-99ER62764/A002]
- NIMH [R01MH084898]
- NIH [NS039123]
Ask authors/readers for more resources
We investigated glutamate-related neuronal dysfunction in the anterior cingulate (AC) early in schizophrenia before and after antipsychotic treatment. A total of 14 minimally treated schizophrenia patients and 10 healthy subjects were studied with single-voxel proton magnetic resonance spectroscopy (H-1-MRS) of the AC, frontal white matter and thalamus at 4 T. Concentrations of N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln) and Gln/Glu ratios were determined and corrected for the partial tissue volume. Patients were treated with antipsychotic medication following a specific algorithm and H-1-MRS was repeated after 1, 6 and 12 months. There were group x region interactions for baseline NAA (P = 0.074) and Gln/Glu (P = 0.028): schizophrenia subjects had lower NAA (P = 0.045) and higher Gln/Glu (P = 0.006) in the AC before treatment. In addition, AC Gln/Glu was inversely related to AC NAA in the schizophrenia (P = 0.0009) but not in the control group (P = 0.92). Following antipsychotic treatment, there were no further changes in NAA, Gln/Glu or any of the other metabolites in any of the regions studied. We conclude that early in the illness, schizophrenia patients already show abnormalities in glutamatergic metabolism and reductions in NAA consistent with glutamate-related excitotoxicity. Molecular Psychiatry (2010) 15, 629-636; doi: 10.1038/mp.2009.121; published online 17 November 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available